← Back to Search

Expressive Writing for Graft-versus-Host Disease (EXPRESS-C-GVHD Trial)

Phase < 1
Waitlist Available
Led By Jennifer Choi
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial investigates a new non-drug therapy for GVHD, a disease where donor cells attack the host body, to improve quality of life. The therapy, called expressive writing, involves writing and talking with others in a support group.

Who is the study for?
This trial is for adults over 18 with chronic cutaneous graft-versus-host disease (cGVHD), who can understand and sign consent, write or type, and have internet to join Zoom sessions. It's not for those with limited English skills.
What is being tested?
The study tests expressive writing within a support group setting as a non-drug therapy to improve distress, systemic disease symptoms, and life quality in patients with skin-related GVHD.
What are the potential side effects?
Since this intervention involves expressive writing rather than medication, traditional side effects are not expected. Participants may experience emotional discomfort while reflecting on their condition.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Dermatology Life Quality Index scores
Secondary study objectives
Change in Short Form-36 scores

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Expressive writing weekly sessionExperimental Treatment1 Intervention
Weekly, 1-hour sessions of creative writing, discussion and social support, in a group setting via videoconference for a total of 4 sessions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Expressive Writing
2011
Completed Phase 3
~1990

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,649 Previous Clinical Trials
958,761 Total Patients Enrolled
Jennifer ChoiPrincipal InvestigatorNorthwestern University

Media Library

Expressive Writing Clinical Trial Eligibility Overview. Trial Name: NCT05694832 — Phase < 1
Graft-versus-Host Disease Research Study Groups: Expressive writing weekly session
Graft-versus-Host Disease Clinical Trial 2023: Expressive Writing Highlights & Side Effects. Trial Name: NCT05694832 — Phase < 1
Expressive Writing 2023 Treatment Timeline for Medical Study. Trial Name: NCT05694832 — Phase < 1
~3 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top